Search clinical trials for: histone deacetylases

Total 728 results

Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

Leukemia | Myelodysplastic Syndrome

United States
Masonic Cancer Center, University of Minnesota

Terminated

Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

United States
Masonic Cancer Center, University of Minnesota
Novartis Pharmaceuticals; Millennium Pharmaceuticals, Inc.

Terminated

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

Pancreatic Cancer

United States
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massey Cancer Center

Withdrawn

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Lymphoma | Relapsed and Refractory Aggressive B- and T-cell Lymphomas

United States
Novartis Pharmaceuticals

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple Myeloma

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Celgene

Completed

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Melanoma | Lymphoma | Multiple Myeloma | Pancreatic Cancer | Non-Small Cell Lung Cancer

Australia
Stanford University

Terminated

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Cutaneous T-cell Lymphoma | Cutaneous Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Novartis; Celgene

Completed

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Singapore
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
National Institute of Neurological Disorders and...

Completed

Measuring Levels of SMN in Blood Samples of SMA Patients

Spinal Muscular Atrophy

United States
Stanford University
National Comprehensive Cancer Network

Completed

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis | Lung Cancer | Brain Cancer

United States
The Methodist Hospital Research Institute

Withdrawn

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT)

Non-Hodgkin Lymphoma
Mirati Therapeutics Inc.

Completed

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Myelodysplastic Syndrome

United States
Tiziana Marangon

Terminated

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

Multiple Myeloma

Italy
Mirati Therapeutics Inc.

Completed

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Urothelial Carcinoma

United States
Novartis Pharmaceuticals

Terminated

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) (GEPARD)

Myelodysplastic Syndrome (MDS)

Germany
National Cancer Institute (NCI)

Terminated

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Thymic Carcinoma | Thymoma

United States
National Cancer Institute (NCI)

Terminated

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC; Boston Children's Hospital; Brigham and Women's Hospital

Terminated

Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia

United States
National Cancer Institute (NCI)

Completed

MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

Sarcoma | Lymphoma | Neuroblastoma | WilmsTumor

United States
University of Iowa
Novartis Pharmaceuticals; Holden Comprehensive Cancer Center

Terminated

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Metastatic Melanoma

United States
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART

HIV-1 Infection

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Ahmad Tarhini
Novartis Pharmaceuticals

Terminated

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

Small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Completed

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

Advanced Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer

United States
University of Aarhus

Completed

Histones and Free-plasma DNA After Cardiac Arrest

Heart Arrest | Hypothermia | Post Cardiac Arrest Syndrome

Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Unresectable Extrahepatic Bile Duct Carcinoma | Recurrent Cholangiocarcinoma | Non-Resectable Cholangiocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IIIA Hilar Cholangiocarcinoma | Stage IIIB Hilar Cholangiocarcinoma | Stage IVA Hilar Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Completed

A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

Esophageal Cancer | Prostate Cancer | Head & Neck Cancer

Belgium
National Cancer Institute (NCI)

Completed

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

Cutaneous T Cell Lymphoma | Peripheral T Cell Lymphoma

United States, Australia
Massachusetts General Hospital
Merck Sharp & Dohme LLC; Dana-Farber Cancer Institute; Brigham and Women's Hospital

Terminated

Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas

Pancreatic Cancer | Adenocarcinoma of the Pancreas

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center

Terminated

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

United States
University of Virginia

Completed

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Bayside Health
Merck Sharp & Dohme LLC

Unknown

Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy

HIV Positive

Australia
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Amgen

Withdrawn

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Multiple Myeloma
M.D. Anderson Cancer Center

Withdrawn

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Lymphoma
National Cancer Institute (NCI)

Terminated

Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditions

Canada, United States
Merck Sharp & Dohme LLC

Terminated

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Breast Cancer | Colorectal Cancer | Non-small-cell Lung Carcinoma
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Celgene

Completed

Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Lymphoma

United States
Gynecologic Oncology Associates
Merck Sharp & Dohme LLC

Terminated

Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma

Ovarian Neoplasms

United States

Search clinical trials for: histone deacetylases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations